Literature DB >> 32180097

Anticancer Actions of Azurin and Its Derived Peptide p28.

Fan Huang1,2, Qianhui Shu1,2, Zhaojie Qin1,2, Jianglin Tian1,2, Zhengding Su1,2, Yongqi Huang1,2, Meng Gao3,4.   

Abstract

Cancers are a great threat to humans. In cancer therapy, surgical removal of the tumor combined with radiotherapy and chemotherapy is the most routine treatment procedure and usually the most effective. However, radiotherapy and chemotherapy drugs that kill cancer cells efficiently also kill normal cells, thus exhibiting large side effects. Cancer-targeted drugs, which aim to specifically recognize proteins or signaling pathways associated with tumor proliferation and migration, have achieved marked progress in recent years. Azurin is a copper-containing redox protein secreted by Pseudomonas aeruginosa. Azurin and its derived peptide p28 preferentially enter a variety of cancer cells and induce apoptosis or cell cycle arrest. Mechanistic studies revealed that azurin and p28 target the p53 and receptor tyrosine kinase signaling pathways as well as other pathways. Two phase I trials of p28 have been carried out, with findings that p28 is safe and exhibits anticancer activity in both adult and pediatric patients. In this review paper, we provide an up-to-date summary of progress on the anticancer mechanisms and therapeutic strategies for azurin and p28.

Entities:  

Keywords:  Anticancer drug; Azurin; Bacterial protein; Tumor suppression; p28

Year:  2020        PMID: 32180097     DOI: 10.1007/s10930-020-09891-3

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  79 in total

1.  Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity.

Authors:  Tohru Yamada; Arsenio M Fialho; Vasu Punj; Laura Bratescu; Tapas K Das Gupta; Ananda M Chakrabarty
Journal:  Cell Microbiol       Date:  2005-10       Impact factor: 3.715

2.  p28-Mediated Activation of p53 in G2-M Phase of the Cell Cycle Enhances the Efficacy of DNA Damaging and Antimitotic Chemotherapy.

Authors:  Tohru Yamada; Tapas K Das Gupta; Craig W Beattie
Journal:  Cancer Res       Date:  2016-02-26       Impact factor: 12.701

Review 3.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

Authors:  Daniel J Hicklin; Lee M Ellis
Journal:  J Clin Oncol       Date:  2004-12-07       Impact factor: 44.544

4.  COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas.

Authors:  David Dornan; Sheila Bheddah; Kim Newton; William Ince; Gretchen D Frantz; Patrick Dowd; Hartmut Koeppen; Vishva M Dixit; Dorothy M French
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

5.  Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells.

Authors:  A S Ribeiro; A Albergaria; B Sousa; A L Correia; M Bracke; R Seruca; F C Schmitt; J Paredes
Journal:  Oncogene       Date:  2009-11-09       Impact factor: 9.867

Review 6.  Recent advances in polymeric micelles for anti-cancer drug delivery.

Authors:  Swati Biswas; Preeti Kumari; Prit Manish Lakhani; Balaram Ghosh
Journal:  Eur J Pharm Sci       Date:  2015-12-31       Impact factor: 4.384

7.  Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5.5 and pH 9.0. A pH-induced conformational transition involves a peptide bond flip.

Authors:  H Nar; A Messerschmidt; R Huber; M van de Kamp; G W Canters
Journal:  J Mol Biol       Date:  1991-10-05       Impact factor: 5.469

Review 8.  Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies.

Authors:  Justine Habault; Jean-Luc Poyet
Journal:  Molecules       Date:  2019-03-07       Impact factor: 4.411

9.  Raman Evidence of p53-DBD Disorder Decrease upon Interaction with the Anticancer Protein Azurin.

Authors:  Sara Signorelli; Salvatore Cannistraro; Anna Rita Bizzarri
Journal:  Int J Mol Sci       Date:  2019-06-24       Impact factor: 5.923

10.  The bacterial protein azurin impairs invasion and FAK/Src signaling in P-cadherin-overexpressing breast cancer cell models.

Authors:  Nuno Bernardes; Ana Sofia Ribeiro; Sofia Abreu; Bruna Mota; Rute G Matos; Cecilia M Arraiano; Raquel Seruca; Joana Paredes; Arsenio M Fialho
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

View more
  3 in total

Review 1.  Antitumour peptide based on a protein derived from the horseshoe crab: CIGB-552 a promising candidate for cancer therapy.

Authors:  Brizaida Oliva Arguelles; Mario Riera-Romo; Maribel Guerra Vallespi
Journal:  Br J Pharmacol       Date:  2020-06-21       Impact factor: 8.739

Review 2.  Lipidomic and Membrane Mechanical Signatures in Triple-Negative Breast Cancer: Scope for Membrane-Based Theranostics.

Authors:  Ruchika Dadhich; Shobhna Kapoor
Journal:  Mol Cell Biochem       Date:  2022-05-20       Impact factor: 3.396

Review 3.  Colorectal cancer treatment using bacteria: focus on molecular mechanisms.

Authors:  Sara Ebrahimzadeh; Hossein Ahangari; Alireza Soleimanian; Kamran Hosseini; Vida Ebrahimi; Tohid Ghasemnejad; Saiedeh Razi Soofiyani; Vahideh Tarhriz; Shirin Eyvazi
Journal:  BMC Microbiol       Date:  2021-07-19       Impact factor: 3.605

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.